Dfpg Investments LLC Lowers Stock Position in West Pharmaceutical Services, Inc. (NYSE:WST)

Dfpg Investments LLC cut its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WSTFree Report) by 15.2% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 685 shares of the medical instruments supplier’s stock after selling 123 shares during the period. Dfpg Investments LLC’s holdings in West Pharmaceutical Services were worth $232,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in WST. Sunbelt Securities Inc. acquired a new stake in shares of West Pharmaceutical Services in the first quarter valued at about $25,000. RVW Wealth LLC acquired a new stake in West Pharmaceutical Services during the third quarter worth approximately $38,000. International Assets Investment Management LLC acquired a new stake in West Pharmaceutical Services during the third quarter worth approximately $53,000. Addison Advisors LLC increased its holdings in shares of West Pharmaceutical Services by 37.9% in the 3rd quarter. Addison Advisors LLC now owns 142 shares of the medical instruments supplier’s stock valued at $53,000 after acquiring an additional 39 shares during the period. Finally, First Horizon Advisors Inc. increased its holdings in shares of West Pharmaceutical Services by 37.4% in the 1st quarter. First Horizon Advisors Inc. now owns 147 shares of the medical instruments supplier’s stock valued at $51,000 after acquiring an additional 40 shares during the period. 91.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at West Pharmaceutical Services

In related news, VP Charles Witherspoon sold 2,019 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $358.62, for a total value of $724,053.78. Following the completion of the transaction, the vice president now owns 1,979 shares of the company’s stock, valued at approximately $709,708.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, VP Charles Witherspoon sold 2,019 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $358.62, for a total value of $724,053.78. Following the completion of the transaction, the vice president now owns 1,979 shares of the company’s stock, valued at approximately $709,708.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Chad Winters sold 815 shares of the business’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $358.82, for a total transaction of $292,438.30. Following the completion of the transaction, the chief accounting officer now directly owns 1,309 shares of the company’s stock, valued at approximately $469,695.38. The disclosure for this sale can be found here. In the last quarter, insiders sold 73,978 shares of company stock valued at $26,653,772. 1.13% of the stock is owned by insiders.

West Pharmaceutical Services Price Performance

West Pharmaceutical Services stock opened at $393.92 on Friday. West Pharmaceutical Services, Inc. has a 52 week low of $310.42 and a 52 week high of $415.73. The company has a quick ratio of 2.24, a current ratio of 2.88 and a debt-to-equity ratio of 0.03. The firm’s 50-day simple moving average is $371.62 and its 200 day simple moving average is $364.20. The firm has a market capitalization of $28.84 billion, a PE ratio of 49.99, a P/E/G ratio of 7.05 and a beta of 1.03.

West Pharmaceutical Services (NYSE:WSTGet Free Report) last released its quarterly earnings data on Thursday, February 15th. The medical instruments supplier reported $1.83 EPS for the quarter, topping the consensus estimate of $1.78 by $0.05. West Pharmaceutical Services had a net margin of 20.12% and a return on equity of 21.60%. The business had revenue of $732.00 million for the quarter, compared to analyst estimates of $740.43 million. During the same period in the previous year, the firm earned $1.77 EPS. The business’s revenue for the quarter was up 3.3% compared to the same quarter last year. On average, equities research analysts predict that West Pharmaceutical Services, Inc. will post 7.62 EPS for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Wednesday, April 24th will be paid a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.20%. The ex-dividend date of this dividend is Tuesday, April 23rd. West Pharmaceutical Services’s payout ratio is 10.15%.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. StockNews.com lowered shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research report on Friday, February 16th. Jefferies Financial Group upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and lifted their price objective for the company from $323.00 to $536.00 in a research report on Wednesday, February 7th. UBS Group lowered their price objective on shares of West Pharmaceutical Services from $400.00 to $375.00 and set a “neutral” rating on the stock in a research report on Friday, February 16th. Finally, KeyCorp lifted their price objective on shares of West Pharmaceutical Services from $440.00 to $470.00 and gave the company an “overweight” rating in a research report on Tuesday, February 13th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, West Pharmaceutical Services currently has an average rating of “Moderate Buy” and an average target price of $435.20.

View Our Latest Report on WST

West Pharmaceutical Services Profile

(Free Report)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Recommended Stories

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WSTFree Report).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.